Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

Université Laval

$188,590.00

Development and bioimaging of blood-brain barrier vectorized nanoparticles

FY 2014-15

Summary
One third of Canadians of all ages will be affected by a brain disease during his or her lifetime. While the population isgetting older, the risk of suffering from Alzheimer, stroke, Parkinson, etc. increases exponentially after age 65. Most peopledo not realize that the socioeconomic burden of brain diseases dwarf those of cancer and cardiovascular disease combined.Unfortunately, the research and development of new drugs for brain diseases lags behind. The main problem resides in thefact that the blood-brain barrier (BBB) severely restricts the passage of drugs from the blood to the brain. The vast majorityof advanced drugs are too large to pass through the BBB and virtually all strategies developed so far to cross the BBBwithout damaging it have failed in humans. Indeed, the brain is like a walled city, in which the BBB represents the wallsurrounding the city. The total length of the BBB of a normal human brain spans approximately 600 km.Here, we are proposing to generate new vectors and determine which one is the best to target the natural transport systemslocated in the BBB. These transport systems are the equivalent of the guarded gates in the walled city analogy, as they allowthe entry of their friends. Then, these vectors will be conjugated to nanoparticles to ferry drugs inside cells of the BBB. Wewill then verify with advances techniques whether our vectorized nanoparticles stay in the BBB or penetrate deeper in thebrain. Such a tactic is reminiscent of the Trojan horse strategy because the nanoparticles are built to trick the brainsscreening system (or city guards). Therefore, the present study could lead to the development of new brain drug deliverysystems for clinical applications in Alzheimers disease and many other brain disorders.
Program
Collaborative Health Research Projects
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
446667-2013
Name nom
Calon, Frederic
Department département
Pharmacie, Faculté de
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2013
Award amount
188590
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2 & 3
Nb partie
3
Application title
Development and bioimaging of blood-brain barrier vectorized nanoparticles
Keyword
NSERC
Application summary
One third of Canadians of all ages will be affected by a brain disease during his or her lifetime. While the population isgetting older, the risk of suffering from Alzheimer, stroke, Parkinson, etc. increases exponentially after age 65. Most peopledo not realize that the socioeconomic burden of brain diseases dwarf those of cancer and cardiovascular disease combined.Unfortunately, the research and development of new drugs for brain diseases lags behind. The main problem resides in thefact that the blood-brain barrier (BBB) severely restricts the passage of drugs from the blood to the brain. The vast majorityof advanced drugs are too large to pass through the BBB and virtually all strategies developed so far to cross the BBBwithout damaging it have failed in humans. Indeed, the brain is like a walled city, in which the BBB represents the wallsurrounding the city. The total length of the BBB of a normal human brain spans approximately 600 km.Here, we are proposing to generate new vectors and determine which one is the best to target the natural transport systemslocated in the BBB. These transport systems are the equivalent of the guarded gates in the walled city analogy, as they allowthe entry of their friends. Then, these vectors will be conjugated to nanoparticles to ferry drugs inside cells of the BBB. Wewill then verify with advances techniques whether our vectorized nanoparticles stay in the BBB or penetrate deeper in thebrain. Such a tactic is reminiscent of the Trojan horse strategy because the nanoparticles are built to trick the brainsscreening system (or city guards). Therefore, the present study could lead to the development of new brain drug deliverysystems for clinical applications in Alzheimers disease and many other brain disorders.
Université Laval - $188,590 Grant (2014-15) | Canada Spends